Apellis Pharmaceuticals, Inc. (APLS)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $8k
- Feb 11 · No plan
- Form 4 sales
- 370
- On record
- Form 144 notices
- 88
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleUnusualJan 22 2026
Sold 10,287 shares at $21.77 ($224k)
Sullivan Timothy Eugene, Chief Financial Officer
No 10b5-1 planSold 9.9% of holdings ($2.3M position)93,901 shares left3.4x usual sizeFiling
- 2 Form 4 saleUnusualJan 22 same day
Sold 7,725 shares at $21.77 ($168k)
Nicholson Nur, Chief Technical Officer
No 10b5-1 planSold 9.8% of holdings ($1.7M position)71,118 shares left3.2x usual sizeFiling
- 3 Form 4 saleNo planJan 22 same day
Sold 27,192 shares at $21.77 ($592k)
Francois Cedric, Chief Executive Officer
No 10b5-1 planSold 8.7% of holdings ($6.8M position)286,045 shares left3x usual sizeFiling
- 4 Form 4 saleNo planJan 22 same day
Sold 5,928 shares at $21.77 ($129k)
Deschatelets Pascal, Chief Scientific Officer
No 10b5-1 planSold 0.5% of holdings ($25.2M position)1.2M shares left2.6x usual sizeFiling
- 5 Form 4 saleNo planJan 22 same day
Sold 3,371 shares at $21.77 ($73k)
DeLong Mark Jeffrey, Chief Business & Strat Officer
No 10b5-1 planSold 4.1% of holdings ($1.8M position)78,353 shares left2.6x usual sizeFiling
- 6 Form 4 saleUnusualJan 22 same day
Sold 2,064 shares at $21.77 ($45k)
Chopas James George, VP/Chief Accounting Officer
No 10b5-1 planSold 4% of holdings ($1.1M position)49,805 shares left3.8x usual sizeFiling
- 7 Form 4 saleNo planJan 22 same day
Sold 2,797 shares at $21.77 ($61k)
Baumal Caroline, Chief Medical Officer
No 10b5-1 planSold 3.1% of holdings ($1.9M position)86,527 shares left1.2x usual sizeFiling
- 8 Form 4 saleNo planFeb 11 +20 days
Sold 368 shares at $22.15 ($8k)
DeLong Mark Jeffrey, Chief Business & Strat Officer
No 10b5-1 planSold 0.3% of holdings ($2.5M position)114,591 shares left0.3x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (newest 400 of 458)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 368 | $8k | 0.3% | No plan | SEC |
| Jan 22, 2026 | Baumal Caroline | Chief Medical Officer | Form 4 sale | 2,797 | $61k | 3.1% | No plan | SEC |
| Jan 22, 2026 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 2,064 | $45k | 4.0% | Unusual | SEC |
| Jan 22, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 3,371 | $73k | 4.1% | No plan | SEC |
| Jan 22, 2026 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 5,928 | $129k | 0.5% | No plan | SEC |
| Jan 22, 2026 | Francois Cedric | Chief Executive Officer | Form 4 sale | 27,192 | $592k | 8.7% | No plan | SEC |
| Jan 22, 2026 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 7,725 | $168k | 9.8% | Unusual | SEC |
| Jan 22, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 10,287 | $224k | 9.9% | Unusual | SEC |
| Jan 22, 2026 | Watson David O. | General Counsel | Form 4 sale | 7,832 | $171k | 8.1% | No plan | SEC |
| Jan 20, 2026 | Baumal Caroline | Chief Medical Officer | Form 4 sale | 1,882 | $37k | 2.1% | No plan | SEC |
| Jan 20, 2026 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 726 | $14k | 1.4% | No plan | SEC |
| Jan 20, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 1,334 | $26k | 1.6% | No plan | SEC |
| Jan 20, 2026 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 909 | $18k | 0.1% | No plan | SEC |
| Jan 20, 2026 | Francois Cedric | Chief Executive Officer | Form 4 sale | 8,182 | $162k | 2.5% | No plan | SEC |
| Jan 20, 2026 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 2,203 | $44k | 2.7% | No plan | SEC |
| Jan 20, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 2,892 | $57k | 2.7% | No plan | SEC |
| Jan 20, 2026 | Watson David O. | General Counsel | Form 4 sale | 2,475 | $49k | 2.5% | No plan | SEC |
| Jan 13, 2026 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 873 | $19k | 1.6% | No plan | SEC |
| Jan 13, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 1,780 | $39k | 2.1% | No plan | SEC |
| Jan 13, 2026 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 2,277 | $51k | 0.2% | No plan | SEC |
| Jan 13, 2026 | Francois Cedric | Chief Executive Officer | Form 4 sale | 10,186 | $226k | 3.1% | No plan | SEC |
| Jan 13, 2026 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 2,618 | $58k | 3.1% | No plan | SEC |
| Jan 13, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 3,856 | $86k | 3.5% | No plan | SEC |
| Jan 13, 2026 | Watson David O. | General Counsel | Form 4 sale | 5,780 | $128k | 5.5% | No plan | SEC |
| Jan 5, 2026 | Baumal Caroline | Chief Medical Officer | Form 4 sale | 3,020 | $77k | 3.2% | No plan | SEC |
| Dec 16, 2025 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $122k | 4.6% | Routine | SEC |
| Nov 17, 2025 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $100k | 4.4% | Routine | SEC |
| Oct 21, 2025 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 10,000 | $280k | 8.3% | Unusual | SEC |
| Oct 16, 2025 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $126k | 4.2% | Routine | SEC |
| Oct 10, 2025 | Dunlop A. Sinclair | Director | Form 4 sale | 31,092 | $738k | 89.0% | Routine | SEC |
| Sep 30, 2025 | Dunlop A. Sinclair | Director | Form 4 sale | 31,092 | $702k | 47.8% | Routine | SEC |
| Sep 19, 2025 | Dunlop A. Sinclair | Director | Form 4 sale | 31,092 | $714k | 31.1% | Routine | SEC |
| Sep 16, 2025 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $122k | 4.0% | Routine | SEC |
| Sep 15, 2025 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 189 | $5k | 0.4% | No plan | SEC |
| Sep 10, 2025 | Watson David O. | General Counsel | Form 4 sale | 20,000 | $523k | 28.5% | Unusual | SEC |
| Sep 8, 2025 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 42,729 | $1.2M | 27.8% | Unusual | SEC |
| Sep 2, 2025 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 548 | $15k | 1.0% | No plan | SEC |
| Aug 28, 2025 | Francois Cedric | Chief Executive Officer | Form 4 sale | 225,000 | $6.4M | 42.2% | Unusual | SEC |
| Aug 18, 2025 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $139k | 3.9% | Routine | SEC |
| Jul 17, 2025 | Francois Cedric | Chief Executive Officer | Form 4 sale | 19,725 | $399k | 5.6% | Routine | SEC |
| Jul 16, 2025 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $98k | 3.7% | Routine | SEC |
| Jul 15, 2025 | Francois Cedric | Chief Executive Officer | Form 4 sale | 139,365 | $2.8M | 28.9% | Unusual | SEC |
| Jun 16, 2025 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $94k | 3.6% | Routine | SEC |
| Mar 17, 2025 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 183 | $5k | 0.4% | No plan | SEC |
| Mar 5, 2025 | Watson David O. | General Counsel | Form 4 sale | 5,569 | $140k | 3.9% | No plan | SEC |
| Feb 11, 2025 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 363 | $10k | 0.4% | No plan | SEC |
| Jan 29, 2025 | Watson David O. | General Counsel | Form 4 sale | 695 | $21k | 0.5% | No plan | SEC |
| Jan 29, 2025 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 695 | $21k | 0.8% | No plan | SEC |
| Jan 29, 2025 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 546 | $16k | 0.4% | No plan | SEC |
| Jan 29, 2025 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 825 | $24k | 1.0% | No plan | SEC |
| Jan 29, 2025 | Lewis Karen | Chief People Officer | Form 4 sale | 364 | $11k | 0.5% | No plan | SEC |
| Jan 29, 2025 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 278 | $8k | 0.5% | No plan | SEC |
| Jan 29, 2025 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 826 | $24k | 0.1% | No plan | SEC |
| Jan 29, 2025 | Francois Cedric | Chief Executive Officer | Form 4 sale | 2,824 | $83k | 0.7% | No plan | SEC |
| Jan 29, 2025 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 365 | $11k | 0.4% | No plan | SEC |
| Jan 22, 2025 | Watson David O. | General Counsel | Form 4 sale | 3,323 | $101k | 2.2% | No plan | SEC |
| Jan 22, 2025 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 3,323 | $101k | 3.8% | No plan | SEC |
| Jan 22, 2025 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 3,088 | $94k | 2.3% | No plan | SEC |
| Jan 22, 2025 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 3,948 | $120k | 4.5% | No plan | SEC |
| Jan 22, 2025 | Lewis Karen | Chief People Officer | Form 4 sale | 1,751 | $53k | 2.4% | No plan | SEC |
| Jan 22, 2025 | Francois Cedric | Chief Executive Officer | Form 4 sale | 13,551 | $412k | 3.1% | No plan | SEC |
| Jan 22, 2025 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 1,291 | $39k | 2.3% | No plan | SEC |
| Jan 22, 2025 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 3,948 | $120k | 0.3% | No plan | SEC |
| Jan 22, 2025 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 1,396 | $42k | 1.6% | No plan | SEC |
| Jan 22, 2025 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 1,096 | $33k | 2.2% | No plan | SEC |
| Jan 17, 2025 | Watson David O. | General Counsel | Form 4 sale | 2,201 | $66k | 2.0% | No plan | SEC |
| Jan 17, 2025 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 2,201 | $66k | 2.4% | No plan | SEC |
| Jan 17, 2025 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 1,730 | $52k | 2.0% | No plan | SEC |
| Jan 17, 2025 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 2,145 | $64k | 4.0% | No plan | SEC |
| Jan 17, 2025 | Lewis Karen | Chief People Officer | Form 4 sale | 1,241 | $37k | 2.8% | No plan | SEC |
| Jan 17, 2025 | Francois Cedric | Chief Executive Officer | Form 4 sale | 6,007 | $180k | 2.0% | No plan | SEC |
| Jan 17, 2025 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 750 | $22k | 0.1% | No plan | SEC |
| Jan 17, 2025 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 1,235 | $37k | 2.1% | No plan | SEC |
| Jan 17, 2025 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 715 | $21k | 1.9% | No plan | SEC |
| Jan 17, 2025 | Baumal Caroline | Chief Medical Officer | Form 4 sale | 1,853 | $56k | 3.3% | No plan | SEC |
| Jan 13, 2025 | Watson David O. | General Counsel | Form 4 sale | 4,965 | $142k | 4.4% | No plan | SEC |
| Jan 13, 2025 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 2,685 | $77k | 2.9% | No plan | SEC |
| Jan 13, 2025 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 2,170 | $62k | 2.4% | No plan | SEC |
| Jan 13, 2025 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 2,632 | $76k | 4.6% | No plan | SEC |
| Jan 13, 2025 | Lewis Karen | Chief People Officer | Form 4 sale | 1,599 | $46k | 3.4% | No plan | SEC |
| Jan 13, 2025 | Francois Cedric | Chief Executive Officer | Form 4 sale | 6,247 | $179k | 2.0% | No plan | SEC |
| Jan 13, 2025 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 264 | $8k | 0.5% | No plan | SEC |
| Jan 13, 2025 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 2,288 | $66k | 0.2% | No plan | SEC |
| Jan 13, 2025 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 1,599 | $46k | 2.6% | No plan | SEC |
| Jan 13, 2025 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 783 | $22k | 2.1% | No plan | SEC |
| Jan 6, 2025 | Baumal Caroline | Chief Medical Officer | Form 4 sale | 2,816 | $95k | 4.8% | No plan | SEC |
| Dec 23, 2024 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 63 | $2k | 0.1% | No plan | SEC |
| Dec 11, 2024 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $171k | 4.2% | No plan | SEC |
| Dec 11, 2024 | Watson David O. | Officer | Form 144 notice | 5,000 | $171k | Notice | SEC | |
| Sep 16, 2024 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 192 | $7k | 0.5% | No plan | SEC |
| Sep 16, 2024 | Dunlop A. Sinclair | Director | Form 4 sale | 37,000 | $1.3M | 27.0% | Unusual | SEC |
| Sep 3, 2024 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 550 | $22k | 1.4% | No plan | SEC |
| Jun 21, 2024 | Dunlop A. Sinclair | Director | Form 4 sale | 37,000 | $1.5M | 21.3% | Unusual | SEC |
| May 8, 2024 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 78,907 | $3.3M | 6.6% | Unusual | SEC |
| Apr 8, 2024 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 69,107 | $3.7M | 5.8% | Unusual | SEC |
| Apr 1, 2024 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 4,000 | $235k | 4.1% | Routine | SEC |
| Mar 19, 2024 | Dunlop A. Sinclair | Director | Form 4 sale | 18,681 | $1.1M | 9.7% | Unusual | SEC |
| Mar 18, 2024 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 9,913 | $564k | 15.3% | No plan | SEC |
| Mar 15, 2024 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 184 | $10k | 0.5% | No plan | SEC |
| Mar 13, 2024 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 11,220 | $646k | 16.6% | Unusual | SEC |
| Mar 8, 2024 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 69,107 | $4.3M | 5.8% | Unusual | SEC |
| Mar 1, 2024 | Francois Cedric | Chief Executive Officer | Form 4 sale | 250,000 | $16M | 44.4% | Unusual | SEC |
| Mar 1, 2024 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 6,000 | $379k | 6.0% | Routine | SEC |
| Feb 12, 2024 | Watson David O. | General Counsel | Form 4 sale | 781 | $53k | 0.7% | No plan | SEC |
| Feb 12, 2024 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 1,148 | $78k | 1.2% | No plan | SEC |
| Feb 12, 2024 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 1,431 | $97k | 1.5% | No plan | SEC |
| Feb 12, 2024 | Francois Cedric | Chief Executive Officer | Form 4 sale | 3,962 | $269k | 1.2% | No plan | SEC |
| Feb 12, 2024 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 1,148 | $78k | 0.1% | No plan | SEC |
| Feb 12, 2024 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 597 | $40k | 0.9% | No plan | SEC |
| Feb 12, 2024 | Francois Cedric | Officer, Director | Form 144 notice | 3,962 | $268k | Notice | SEC | |
| Feb 12, 2024 | Watson David O. | Officer | Form 144 notice | 781 | $53k | Notice | SEC | |
| Feb 12, 2024 | Townsend Adam J. | Officer | Form 144 notice | 1,148 | $78k | Notice | SEC | |
| Feb 12, 2024 | DeLong Mark Jeffrey | Officer | Form 144 notice | 597 | $40k | Notice | SEC | |
| Feb 12, 2024 | Sullivan Timothy Eugene | Officer | Form 144 notice | 1,431 | $97k | Notice | SEC | |
| Feb 12, 2024 | Deschatelets Pascal | Officer | Form 144 notice | 1,148 | $78k | Notice | SEC | |
| Jan 30, 2024 | Lewis Karen | Chief People Officer | Form 4 sale | 1,250 | $81k | 2.6% | Routine | SEC |
| Jan 30, 2024 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 1,250 | $82k | 2.1% | Routine | SEC |
| Jan 30, 2024 | Eisele Jeffrey | Officer | Form 144 notice | 971 | $64k | Notice | SEC | |
| Jan 30, 2024 | Lewis Karen | Officer | Form 144 notice | 883 | $58k | Notice | SEC | |
| Jan 29, 2024 | Watson David O. | General Counsel | Form 4 sale | 906 | $58k | 0.9% | No plan | SEC |
| Jan 29, 2024 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 906 | $58k | 1.0% | No plan | SEC |
| Jan 29, 2024 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 906 | $58k | 0.9% | No plan | SEC |
| Jan 29, 2024 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 835 | $54k | 1.2% | No plan | SEC |
| Jan 29, 2024 | Francois Cedric | Chief Executive Officer | Form 4 sale | 2,843 | $182k | 0.9% | No plan | SEC |
| Jan 29, 2024 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 874 | $56k | 0.1% | No plan | SEC |
| Jan 29, 2024 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 367 | $24k | 0.6% | No plan | SEC |
| Jan 29, 2024 | Eisele Jeffrey | Officer | Form 144 notice | 279 | $18k | Notice | SEC | |
| Jan 29, 2024 | Sullivan Timothy Eugene | Officer | Form 144 notice | 906 | $58k | Notice | SEC | |
| Jan 29, 2024 | Watson David O. | Officer | Form 144 notice | 906 | $58k | Notice | SEC | |
| Jan 29, 2024 | Francois Cedric | Officer, Director | Form 144 notice | 2,843 | $182k | Notice | SEC | |
| Jan 29, 2024 | Lewis Karen | Officer | Form 144 notice | 367 | $24k | Notice | SEC | |
| Jan 29, 2024 | Nicholson Nur | Officer | Form 144 notice | 835 | $54k | Notice | SEC | |
| Jan 29, 2024 | DeLong Mark Jeffrey | Officer | Form 144 notice | 367 | $24k | Notice | SEC | |
| Jan 29, 2024 | Townsend Adam J. | Officer | Form 144 notice | 906 | $58k | Notice | SEC | |
| Jan 29, 2024 | Deschatelets Pascal | Officer | Form 144 notice | 874 | $56k | Notice | SEC | |
| Jan 23, 2024 | Lewis Karen | Chief People Officer | Form 4 sale | 4,286 | $273k | 8.3% | Routine | SEC |
| Jan 23, 2024 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 7,378 | $470k | 11.2% | Unusual | SEC |
| Jan 23, 2024 | Eisele Jeffrey | Officer | Form 144 notice | 7,378 | $470k | Notice | SEC | |
| Jan 23, 2024 | Lewis Karen | Officer | Form 144 notice | 4,286 | $273k | Notice | SEC | |
| Jan 22, 2024 | Francois Cedric | Chief Executive Officer | Form 4 sale | 13,431 | $873k | 4.0% | No plan | SEC |
| Jan 22, 2024 | Watson David O. | General Counsel | Form 4 sale | 4,184 | $272k | 3.8% | No plan | SEC |
| Jan 22, 2024 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 3,413 | $222k | 3.5% | No plan | SEC |
| Jan 22, 2024 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 3,551 | $231k | 3.6% | No plan | SEC |
| Jan 22, 2024 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 2,593 | $169k | 3.7% | No plan | SEC |
| Jan 22, 2024 | Lewis Karen | Chief People Officer | Form 4 sale | 1,738 | $113k | 3.2% | No plan | SEC |
| Jan 22, 2024 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 1,607 | $104k | 2.4% | No plan | SEC |
| Jan 22, 2024 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 3,913 | $254k | 0.3% | No plan | SEC |
| Jan 22, 2024 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 1,384 | $90k | 2.1% | No plan | SEC |
| Jan 22, 2024 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 1,061 | $69k | 2.6% | No plan | SEC |
| Jan 22, 2024 | Lewis Karen | Officer | Form 144 notice | 1,738 | $113k | Notice | SEC | |
| Jan 22, 2024 | Deschatelets Pascal | Officer | Form 144 notice | 3,913 | $254k | Notice | SEC | |
| Jan 22, 2024 | Eisele Jeffrey | Officer | Form 144 notice | 1,607 | $104k | Notice | SEC | |
| Jan 22, 2024 | Nicholson Nur | Officer | Form 144 notice | 2,593 | $169k | Notice | SEC | |
| Jan 22, 2024 | Sullivan Timothy Eugene | Officer | Form 144 notice | 3,551 | $231k | Notice | SEC | |
| Jan 22, 2024 | DeLong Mark Jeffrey | Officer | Form 144 notice | 1,384 | $90k | Notice | SEC | |
| Jan 22, 2024 | Watson David O. | Officer | Form 144 notice | 4,184 | $272k | Notice | SEC | |
| Jan 22, 2024 | Francois Cedric | Officer, Director | Form 144 notice | 13,431 | $873k | Notice | SEC | |
| Jan 22, 2024 | Chopas James George | Officer | Form 144 notice | 1,061 | $69k | Notice | SEC | |
| Jan 22, 2024 | Townsend Adam J. | Officer | Form 144 notice | 3,413 | $222k | Notice | SEC | |
| Jan 17, 2024 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 5,207 | $341k | 7.2% | Unusual | SEC |
| Jan 17, 2024 | Lewis Karen | Chief People Officer | Form 4 sale | 3,276 | $215k | 5.8% | Routine | SEC |
| Jan 17, 2024 | Eisele Jeffrey | Officer | Form 144 notice | 5,207 | $341k | Notice | SEC | |
| Jan 17, 2024 | Lewis Karen | Officer | Form 144 notice | 3,276 | $215k | Notice | SEC | |
| Jan 16, 2024 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 1,632 | $109k | 0.1% | No plan | SEC |
| Jan 16, 2024 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 864 | $58k | 2.1% | No plan | SEC |
| Jan 16, 2024 | Lewis Karen | Chief People Officer | Form 4 sale | 1,632 | $109k | 2.8% | No plan | SEC |
| Jan 16, 2024 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 1,631 | $109k | 2.4% | No plan | SEC |
| Jan 16, 2024 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 1,857 | $124k | 2.6% | No plan | SEC |
| Jan 16, 2024 | Watson David O. | General Counsel | Form 4 sale | 4,240 | $283k | 3.7% | No plan | SEC |
| Jan 16, 2024 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 2,235 | $149k | 2.2% | No plan | SEC |
| Jan 16, 2024 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 2,235 | $149k | 2.2% | No plan | SEC |
| Jan 16, 2024 | Francois Cedric | Chief Executive Officer | Form 4 sale | 7,851 | $525k | 2.3% | No plan | SEC |
| Jan 16, 2024 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 438 | $29k | 0.6% | No plan | SEC |
| Jan 16, 2024 | Townsend Adam J. | Officer | Form 144 notice | 2,235 | $149k | Notice | SEC | |
| Jan 16, 2024 | Deschatelets Pascal | Officer | Form 144 notice | 1,632 | $109k | Notice | SEC | |
| Jan 16, 2024 | Lewis Karen | Officer | Form 144 notice | 1,632 | $109k | Notice | SEC | |
| Jan 16, 2024 | Chopas James George | Officer | Form 144 notice | 864 | $58k | Notice | SEC | |
| Jan 16, 2024 | Francois Cedric | Officer, Director | Form 144 notice | 7,851 | $525k | Notice | SEC | |
| Jan 16, 2024 | Eisele Jeffrey | Officer | Form 144 notice | 438 | $29k | Notice | SEC | |
| Jan 16, 2024 | Nicholson Nur | Officer | Form 144 notice | 1,857 | $124k | Notice | SEC | |
| Jan 16, 2024 | DeLong Mark Jeffrey | Officer | Form 144 notice | 1,631 | $109k | Notice | SEC | |
| Jan 16, 2024 | Watson David O. | Officer | Form 144 notice | 4,240 | $283k | Notice | SEC | |
| Jan 16, 2024 | Sullivan Timothy Eugene | Officer | Form 144 notice | 2,235 | $149k | Notice | SEC | |
| Jan 4, 2024 | Baumal Caroline | Chief Medical Officer | Form 4 sale | 2,751 | $165k | 7.7% | No plan | SEC |
| Jan 4, 2024 | Baumal Caroline | Officer | Form 144 notice | 2,751 | $165k | Notice | SEC | |
| Dec 27, 2023 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 303 | $18k | 0.6% | Routine | SEC |
| Dec 27, 2023 | Eisele Jeffrey | Officer | Form 144 notice | 235 | $14k | Notice | SEC | |
| Dec 26, 2023 | Eisele Jeffrey | Officer | Form 144 notice | 68 | $4k | Notice | SEC | |
| Dec 19, 2023 | Watson David O. | General Counsel | Form 4 sale | 3,905 | $223k | 4.2% | No plan | SEC |
| Dec 19, 2023 | Watson David O. | Officer | Form 144 notice | 3,905 | $223k | Notice | SEC | |
| Dec 1, 2023 | Scheibler Lukas | Chief Research Officer | Form 4 sale | 10,000 | $600k | 12.8% | Routine | SEC |
| Dec 1, 2023 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 110,000 | $6.7M | 59.0% | Unusual | SEC |
| Dec 1, 2023 | Dunlop A. Sinclair | Director | Form 4 sale | 24,000 | $1.5M | 11.1% | Unusual | SEC |
| Dec 1, 2023 | Dunlop A. Sinclair | Director | Form 144 notice | 24,000 | $1.3M | Notice | SEC | |
| Dec 1, 2023 | Townsend Adam J. | Officer | Form 144 notice | 110,000 | $6.8M | Notice | SEC | |
| Dec 1, 2023 | Scheibler Lukas | Officer | Form 144 notice | 10,000 | $600k | Notice | SEC | |
| Nov 30, 2023 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 14,158 | $775k | 15.4% | Routine | SEC |
| Nov 30, 2023 | Sullivan Timothy Eugene | Officer | Form 144 notice | 14,158 | $775k | Notice | SEC | |
| Nov 21, 2023 | Francois Cedric | Chief Executive Officer | Form 4 sale | 5,000 | $244k | 1.8% | No plan | SEC |
| Nov 21, 2023 | Francois Cedric | Officer, Director | Form 144 notice | 5,000 | $245k | Notice | SEC | |
| Nov 17, 2023 | Dunlop A. Sinclair | Director | Form 4 sale | 8,894 | $445k | 6.8% | Unusual | SEC |
| Nov 17, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $60k | 0.3% | Routine | SEC |
| Nov 17, 2023 | Dunlop A. Sinclair | Director | Form 144 notice | 8,894 | $445k | Notice | SEC | |
| Nov 17, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $60k | Notice | SEC | |
| Nov 9, 2023 | Dunlop A. Sinclair | Director | Form 144 notice | 24,000 | $1.2M | Notice | SEC | |
| Nov 8, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $567k | 1.1% | Routine | SEC |
| Nov 8, 2023 | Deschatelets Pascal | Officer | Form 144 notice | 12,000 | $567k | Notice | SEC | |
| Oct 23, 2023 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 132 | $6k | 0.4% | No plan | SEC |
| Oct 23, 2023 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Form 4 sale | 131 | $6k | 0.3% | No plan | SEC |
| Oct 23, 2023 | DeLong Mark Jeffrey | Officer | Form 144 notice | 131 | $6k | Notice | SEC | |
| Oct 23, 2023 | Chopas James George | Officer | Form 144 notice | 132 | $6k | Notice | SEC | |
| Oct 17, 2023 | Dunlop A. Sinclair | Director | Form 4 sale | 24,000 | $1.2M | 10.0% | Unusual | SEC |
| Oct 17, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $61k | 0.3% | Routine | SEC |
| Oct 17, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $61k | Notice | SEC | |
| Oct 10, 2023 | Deschatelets Pascal | Officer | Form 144 notice | 12,000 | $485k | Notice | SEC | |
| Oct 9, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $485k | 1.1% | Routine | SEC |
| Sep 18, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $56k | 0.3% | Routine | SEC |
| Sep 18, 2023 | Nicholson Nur | Chief Technical Officer | Form 4 sale | 20,350 | $901k | 27.6% | Unusual | SEC |
| Sep 18, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $56k | Notice | SEC | |
| Sep 18, 2023 | Nicholson Nur | Officer | Form 144 notice | 20,350 | $940k | Notice | SEC | |
| Sep 15, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $57k | 0.3% | Routine | SEC |
| Sep 15, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $57k | Notice | SEC | |
| Sep 8, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $514k | 1.1% | Routine | SEC |
| Sep 8, 2023 | Deschatelets Pascal | Officer | Form 144 notice | 12,000 | $514k | Notice | SEC | |
| Sep 6, 2023 | Scheibler Lukas | Chief Research Officer | Form 4 sale | 1,756 | $76k | 2.5% | No plan | SEC |
| Sep 6, 2023 | Scheibler Lukas | Officer | Form 144 notice | 1,756 | $76k | Notice | SEC | |
| Sep 1, 2023 | Francois Cedric | Chief Executive Officer | Form 4 sale | 150,000 | $6.3M | 26.1% | Unusual | SEC |
| Sep 1, 2023 | Francois Cedric | Officer, Director | Form 144 notice | 150,000 | $6.3M | Notice | SEC | |
| Aug 31, 2023 | Chopas James George | VP/Chief Accounting Officer | Form 4 sale | 551 | $23k | 1.8% | No plan | SEC |
| Aug 31, 2023 | Chopas James George | Officer | Form 144 notice | 551 | $23k | Notice | SEC | |
| Aug 8, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $284k | 1.1% | Routine | SEC |
| Aug 8, 2023 | Deschatelets Pascal | Officer | Form 144 notice | 12,000 | $284k | Notice | SEC | |
| Jul 17, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $81k | 0.5% | Routine | SEC |
| Jul 17, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $81k | Notice | SEC | |
| Jul 10, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $1M | 1.1% | Routine | SEC |
| Jul 10, 2023 | Deschatelets Pascal | Officer | Form 144 notice | 12,000 | $1M | Notice | SEC | |
| Jul 3, 2023 | Watson David O. | General Counsel | Form 4 sale | 8,510 | $766k | 9.0% | Routine | SEC |
| Jul 3, 2023 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 6,779 | $610k | 8.0% | Routine | SEC |
| Jul 3, 2023 | Sullivan Timothy Eugene | Officer | Form 144 notice | 6,779 | $610k | Notice | SEC | |
| Jul 3, 2023 | Watson David O. | Officer | Form 144 notice | 8,510 | $766k | Notice | SEC | |
| Jun 20, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $111k | 0.5% | Routine | SEC |
| Jun 20, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $111k | Notice | SEC | |
| Jun 8, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $1.1M | 1.1% | Routine | SEC |
| Jun 8, 2023 | Deschatelets Pascal | Officer | Form 144 notice | 12,000 | $1.1M | Notice | SEC | |
| Jun 5, 2023 | Sullivan Timothy Eugene | Chief Financial Officer | Form 4 sale | 69,779 | $6.2M | 47.3% | Routine | SEC |
| Jun 5, 2023 | Sullivan Timothy Eugene | Officer | Form 144 notice | 69,779 | $6.1M | Notice | SEC | |
| Jun 1, 2023 | Lewis Karen | Chief People Officer | Form 4 sale | 5,000 | $430k | 10.8% | Routine | SEC |
| Jun 1, 2023 | Lewis Karen | Officer | Form 144 notice | 5,000 | $430k | Notice | SEC | |
| May 17, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $111k | 0.5% | Routine | SEC |
| May 17, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $111k | Notice | SEC | |
| May 16, 2023 | Francois Cedric | Chief Executive Officer | Form 4 sale | 30,000 | $2.6M | 9.8% | No plan | SEC |
| May 16, 2023 | Francois Cedric | Officer | Form 144 notice | 30,000 | $2.6M | Notice | SEC | |
| May 8, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $1.1M | 1.1% | Routine | SEC |
| May 8, 2023 | Deschatelets Pascal | Officer | Form 144 notice | 12,000 | $1.1M | Notice | SEC | |
| May 3, 2023 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $414k | 6.2% | Routine | SEC |
| May 3, 2023 | Townsend Adam J. | Officer | Form 144 notice | 5,000 | $414k | Notice | SEC | |
| May 1, 2023 | Grossi Federico | Officer | Form 144 notice | 2,500 | $193k | Notice | SEC | |
| Apr 18, 2023 | Francois Cedric | Chief Executive Officer | Form 4 sale | 30,000 | $2.5M | 4.5% | Routine | SEC |
| Apr 18, 2023 | Francois Cedric | Officer, Director | Form 144 notice | 30,000 | $2.5M | Notice | SEC | |
| Apr 17, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $101k | 0.5% | Routine | SEC |
| Apr 17, 2023 | Grossi Federico | Officer | Form 144 notice | 4,000 | $328k | Notice | SEC | |
| Apr 17, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $101k | Notice | SEC | |
| Apr 10, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $939k | 1.2% | Routine | SEC |
| Apr 10, 2023 | Deschatelets Pascal | Officer | Form 144 notice | 12,000 | $939k | Notice | SEC | |
| Apr 3, 2023 | Dunlop A. Sinclair | Director | Form 4 sale | 500 | $37k | 0.4% | Routine | SEC |
| Apr 3, 2023 | Lewis Karen | Chief People Officer | Form 4 sale | 5,000 | $375k | 10.8% | Unusual | SEC |
| Apr 3, 2023 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $370k | 6.2% | Routine | SEC |
| Apr 3, 2023 | Townsend Adam J. | Officer | Form 144 notice | 5,000 | $370k | Notice | SEC | |
| Apr 3, 2023 | Grossi Federico | Former Officer | Form 144 notice | 2,500 | $185k | Notice | SEC | |
| Mar 21, 2023 | Francois Cedric | Chief Executive Officer | Form 4 sale | 30,000 | $1.9M | 2.6% | No plan | SEC |
| Mar 21, 2023 | Francois Cedric | Officer | Form 144 notice | 30,000 | $1.9M | Notice | SEC | |
| Mar 17, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $80k | 0.5% | No plan | SEC |
| Mar 17, 2023 | Machiels Alec | Director | Form 144 notice | 1,250 | $80k | Notice | SEC | |
| Mar 8, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $765k | 1.2% | Plan not stated | SEC |
| Mar 3, 2023 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $319k | 6.2% | Plan not stated | SEC |
| Mar 1, 2023 | Dunlop A. Sinclair | Director | Form 4 sale | 500 | $33k | 0.4% | Plan not stated | SEC |
| Feb 23, 2023 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 1,646 | $113k | 3.0% | Plan not stated | SEC |
| Feb 23, 2023 | Lewis Karen | Chief People Officer | Form 4 sale | 1,104 | $76k | 2.6% | Plan not stated | SEC |
| Feb 17, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $65k | 0.5% | Plan not stated | SEC |
| Feb 8, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $653k | 1.2% | Plan not stated | SEC |
| Feb 3, 2023 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $279k | 6.9% | Plan not stated | SEC |
| Feb 1, 2023 | Dunlop A. Sinclair | Director | Form 4 sale | 500 | $26k | 0.4% | Plan not stated | SEC |
| Jan 30, 2023 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 883 | $47k | 1.9% | Plan not stated | SEC |
| Jan 30, 2023 | Lewis Karen | Chief People Officer | Form 4 sale | 883 | $47k | 2.4% | Plan not stated | SEC |
| Jan 23, 2023 | Lewis Karen | Chief People Officer | Form 4 sale | 2,955 | $152k | 7.3% | Plan not stated | SEC |
| Jan 23, 2023 | Eisele Jeffrey | Chief Development Officer | Form 4 sale | 4,479 | $231k | 8.6% | Plan not stated | SEC |
| Jan 17, 2023 | Machiels Alec | Director | Form 4 sale | 1,250 | $66k | 0.5% | Plan not stated | SEC |
| Jan 9, 2023 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $553k | 1.2% | Plan not stated | SEC |
| Jan 5, 2023 | Grossi Federico | Chief Medical Officer | Form 4 sale | 2,500 | $122k | 2.6% | Unusual | SEC |
| Jan 3, 2023 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $254k | 10.4% | Plan not stated | SEC |
| Jan 3, 2023 | Dunlop A. Sinclair | Director | Form 4 sale | 500 | $25k | 0.4% | Plan not stated | SEC |
| Dec 19, 2022 | Francois Cedric | Chief Executive Officer | Form 4 sale | 28,200 | $1.5M | 2.8% | Plan not stated | SEC |
| Dec 15, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $65k | 0.5% | Plan not stated | SEC |
| Dec 8, 2022 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $570k | 1.2% | Plan not stated | SEC |
| Dec 5, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $252k | 10.4% | Plan not stated | SEC |
| Dec 1, 2022 | Dunlop A. Sinclair | Director | Form 4 sale | 500 | $25k | 0.4% | Plan not stated | SEC |
| Dec 1, 2022 | Grossi Federico | Chief Medical Officer | Form 4 sale | 2,500 | $125k | 2.5% | Unusual | SEC |
| Nov 15, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $60k | 0.5% | Plan not stated | SEC |
| Nov 8, 2022 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $558k | 1.2% | Plan not stated | SEC |
| Nov 3, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $293k | 10.4% | Plan not stated | SEC |
| Nov 1, 2022 | Dunlop A. Sinclair | Director | Form 4 sale | 500 | $30k | 0.4% | Plan not stated | SEC |
| Nov 1, 2022 | Grossi Federico | Chief Medical Officer | Form 4 sale | 2,500 | $152k | 2.4% | Unusual | SEC |
| Oct 14, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $74k | 0.5% | Plan not stated | SEC |
| Oct 10, 2022 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $690k | 1.2% | Plan not stated | SEC |
| Oct 3, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 2,500 | $167k | 2.4% | Unusual | SEC |
| Oct 3, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $333k | 10.4% | Plan not stated | SEC |
| Sep 15, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $83k | 0.5% | Plan not stated | SEC |
| Sep 8, 2022 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $768k | 1.2% | Plan not stated | SEC |
| Sep 8, 2022 | Dunlop A. Sinclair | Director | Form 4 sale | 15,000 | $975k | 5.9% | Plan not stated | SEC |
| Sep 6, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $302k | 10.4% | Plan not stated | SEC |
| Sep 1, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 2,500 | $151k | 2.3% | Unusual | SEC |
| Aug 17, 2022 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 5,000 | $348k | 14.6% | Plan not stated | SEC |
| Aug 15, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 12,500 | $863k | 22.6% | Plan not stated | SEC |
| Aug 15, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $84k | 0.5% | Plan not stated | SEC |
| Aug 11, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 12,500 | $838k | 22.6% | Plan not stated | SEC |
| Aug 11, 2022 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 5,000 | $335k | 14.6% | Plan not stated | SEC |
| Aug 11, 2022 | Dunlop A. Sinclair | Director | Form 4 sale | 30,000 | $2M | 10.5% | Plan not stated | SEC |
| Aug 8, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 12,500 | $813k | 22.6% | Plan not stated | SEC |
| Aug 8, 2022 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $750k | 1.3% | Plan not stated | SEC |
| Aug 8, 2022 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 5,000 | $323k | 14.6% | Plan not stated | SEC |
| Aug 4, 2022 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 10,000 | $608k | 25.5% | Unusual | SEC |
| Aug 3, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $282k | 11.7% | Plan not stated | SEC |
| Aug 1, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 2,500 | $140k | 2.3% | Unusual | SEC |
| Jul 27, 2022 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 5,000 | $285k | 14.6% | Plan not stated | SEC |
| Jul 19, 2022 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 5,000 | $282k | 14.6% | Plan not stated | SEC |
| Jul 15, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $58k | 0.5% | Plan not stated | SEC |
| Jul 11, 2022 | Townsend Adam J. | Chief Commercial Officer | Form 4 sale | 5,000 | $242k | 10.4% | Plan not stated | SEC |
| Jul 8, 2022 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $575k | 1.3% | Plan not stated | SEC |
| Jun 27, 2022 | Dunlop A. Sinclair | Director | Form 4 sale | 1,341 | $63k | 50.0% | Unusual | SEC |
| Jun 23, 2022 | Dunlop A. Sinclair | Director | Form 4 sale | 15,000 | $675k | 5.0% | Plan not stated | SEC |
| Jun 22, 2022 | Watson David O. | General Counsel | Form 4 sale | 10,000 | $445k | 8.0% | Plan not stated | SEC |
| Jun 17, 2022 | Brown Victoria L. | Program Team Lead | Form 4 sale | 2,698 | $121k | 9.7% | Plan not stated | SEC |
| Jun 16, 2022 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 10,000 | $418k | 25.5% | Unusual | SEC |
| Jun 15, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $49k | 0.5% | Plan not stated | SEC |
| Jun 8, 2022 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 12,000 | $529k | 1.3% | Plan not stated | SEC |
| Jun 1, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 2,500 | $104k | 2.2% | Unusual | SEC |
| May 27, 2022 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 10,000 | $430k | 19.9% | Plan not stated | SEC |
| May 16, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $49k | 0.5% | Plan not stated | SEC |
| May 2, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 2,500 | $109k | 2.2% | Unusual | SEC |
| Apr 29, 2022 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 4,000 | $178k | 0.4% | Plan not stated | SEC |
| Apr 25, 2022 | Watson David O. | General Counsel | Form 4 sale | 5,000 | $250k | 3.8% | Plan not stated | SEC |
| Apr 20, 2022 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 7,000 | $368k | 19.7% | Unusual | SEC |
| Apr 14, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $64k | 0.5% | Plan not stated | SEC |
| Apr 5, 2022 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 609 | $37k | 1.2% | Plan not stated | SEC |
| Apr 4, 2022 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 3,504 | $200k | 6.3% | Plan not stated | SEC |
| Apr 1, 2022 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 11,496 | $633k | 18.0% | Unusual | SEC |
| Mar 15, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 375 | $15k | 0.3% | Plan not stated | SEC |
| Mar 15, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $49k | 0.5% | Plan not stated | SEC |
| Mar 1, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 375 | $16k | 0.3% | Plan not stated | SEC |
| Feb 15, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 375 | $17k | 0.4% | Plan not stated | SEC |
| Feb 15, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $57k | 0.2% | Plan not stated | SEC |
| Feb 11, 2022 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 1,666 | $78k | 3.1% | Plan not stated | SEC |
| Feb 10, 2022 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 10,000 | $500k | 15.8% | Plan not stated | SEC |
| Feb 8, 2022 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 10,000 | $450k | 15.7% | Plan not stated | SEC |
| Feb 1, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 375 | $15k | 0.4% | Plan not stated | SEC |
| Jan 31, 2022 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 1,233 | $47k | 2.2% | Plan not stated | SEC |
| Jan 14, 2022 | Machiels Alec | Director | Form 4 sale | 1,250 | $51k | 0.2% | Plan not stated | SEC |
| Jan 14, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 375 | $15k | 0.5% | Plan not stated | SEC |
| Jan 3, 2022 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 375 | $18k | 0.5% | Plan not stated | SEC |
| Dec 27, 2021 | Watson David O. | General Counsel | Form 4 sale | 1,200 | $58k | 1.1% | Plan not stated | SEC |
| Dec 22, 2021 | Watson David O. | General Counsel | Form 4 sale | 10,571 | $505k | 8.9% | Plan not stated | SEC |
| Dec 15, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 375 | $16k | 0.5% | Plan not stated | SEC |
| Dec 15, 2021 | Machiels Alec | Director | Form 4 sale | 3,000 | $129k | 0.4% | Plan not stated | SEC |
| Dec 1, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 375 | $16k | 0.6% | Plan not stated | SEC |
| Nov 15, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 625 | $27k | 1.0% | Plan not stated | SEC |
| Nov 15, 2021 | Machiels Alec | Director | Form 4 sale | 6,000 | $236k | 0.9% | Plan not stated | SEC |
| Nov 1, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 625 | $19k | 1.0% | Plan not stated | SEC |
| Oct 14, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 750 | $26k | 1.1% | Plan not stated | SEC |
| Oct 1, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 750 | $25k | 1.1% | Plan not stated | SEC |
| Aug 16, 2021 | Machiels Alec | Director | Form 4 sale | 2,500 | $142k | 0.4% | Plan not stated | SEC |
| Aug 2, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 250 | $16k | 0.4% | Plan not stated | SEC |
| Aug 2, 2021 | Perry Nicole D | Vice President - Accounting | Form 4 sale | 1,000 | $64k | 17.1% | Plan not stated | SEC |
| Jul 21, 2021 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 1,000 | $65k | 9.5% | Plan not stated | SEC |
| Jul 15, 2021 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 1,000 | $62k | 9.5% | Plan not stated | SEC |
| Jul 15, 2021 | Machiels Alec | Director | Form 4 sale | 2,500 | $156k | 0.4% | Plan not stated | SEC |
| Jul 14, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 500 | $32k | 0.8% | Plan not stated | SEC |
| Jul 8, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 250 | $16k | 0.4% | Plan not stated | SEC |
| Jul 1, 2021 | Perry Nicole D | Vice President - Accounting | Form 4 sale | 1,000 | $64k | 17.1% | Plan not stated | SEC |
| Jun 24, 2021 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 6,250 | $410k | 0.7% | Plan not stated | SEC |
| Jun 15, 2021 | Machiels Alec | Director | Form 4 sale | 2,500 | $162k | 0.4% | Plan not stated | SEC |
| Jun 15, 2021 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 4,000 | $260k | 29.7% | Unusual | SEC |
| Jun 14, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 500 | $31k | 0.9% | Plan not stated | SEC |
| Jun 11, 2021 | Perry Nicole D | Vice President - Accounting | Form 4 sale | 1,000 | $62k | 17.1% | Plan not stated | SEC |
| Jun 10, 2021 | Scheibler Lukas | CHIEF INNOVATION OFFICER | Form 4 sale | 3,417 | $205k | 11.4% | Plan not stated | SEC |
| Jun 1, 2021 | Perry Nicole D | Vice President - Accounting | Form 4 sale | 1,000 | $56k | 17.1% | Plan not stated | SEC |
| May 24, 2021 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 6,250 | $296k | 0.7% | Plan not stated | SEC |
| May 20, 2021 | Dunlop A. Sinclair | Director | Form 4 sale | 162,873 | $8.6M | 83.6% | Unusual | SEC |
| May 18, 2021 | DeLong Mark Jeffrey | Senior Vice President | Form 4 sale | 2,000 | $110k | 17.4% | Plan not stated | SEC |
| May 14, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 500 | $23k | 0.9% | Plan not stated | SEC |
| May 14, 2021 | Machiels Alec | Director | Form 4 sale | 2,500 | $113k | 0.4% | Plan not stated | SEC |
| May 3, 2021 | Perry Nicole D | Vice President - Accounting | Form 4 sale | 1,000 | $51k | 17.1% | Plan not stated | SEC |
| May 3, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 600 | $30k | 1.1% | Plan not stated | SEC |
| Apr 30, 2021 | Perry Nicole D | Vice President - Accounting | Form 4 sale | 1,000 | $50k | 17.1% | Plan not stated | SEC |
| Apr 23, 2021 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 6,250 | $288k | 0.7% | Plan not stated | SEC |
| Apr 21, 2021 | Machiels Alec | Director | Form 4 sale | 2,500 | $114k | 0.4% | Plan not stated | SEC |
| Apr 14, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 500 | $21k | 0.9% | Plan not stated | SEC |
| Apr 1, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 600 | $26k | 1.0% | Plan not stated | SEC |
| Mar 15, 2021 | Machiels Alec | Director | Form 4 sale | 2,500 | $117k | 0.4% | Plan not stated | SEC |
| Mar 15, 2021 | Grossi Federico | CHIEF MEDICAL OFFICER | Form 4 sale | 500 | $23k | 0.9% | Plan not stated | SEC |
| Mar 10, 2021 | Deschatelets Pascal | Chief Scientific Officer | Form 4 sale | 6,250 | $317k | 0.7% | Plan not stated | SEC |